NeuroHope Therapeutics

Executive Summary

NeuroHope Therapeutics is a preclinical-stage biotechnology company focused on developing polymeric nanoparticle drug delivery systems for central nervous system (CNS) trauma and neurodegenerative diseases. The company's proprietary PgP polymeric carrier enables local, sustained drug delivery to enhance motor and cognitive functional recovery. Its lead candidate, Rm-PgP, is a micellar nanotherapeutic loaded with rolipram, designed to treat spinal cord injury (SCI) and traumatic brain injury (TBI). By addressing the significant unmet need in CNS conditions where current therapies are limited, NeuroHope aims to improve outcomes for patients suffering from these debilitating injuries. The company is based in Cambridge, MA, and was founded in 2020. As a private, pre-clinical entity, NeuroHope has not yet disclosed total funding or valuation, and its progress is closely watched by investors interested in CNS drug delivery innovations.

Upcoming Catalysts (preview)

• Q4 2026Preclinical proof-of-concept data for Rm-PgP in SCI/TBI models40% success
• H1 2027IND-enabling studies initiation for Rm-PgP30% success
• 2027Partnership or licensing agreement for CNS delivery platform20% success